AI and the Transformation of Life Sciences: What Does the Future Hold?

Aug 6, 2018

From accelerating scientific breakthrough and spotting previously elusive patterns in unwieldy global data masses, to enabling greater drug personalisation, AI and machine learning could help change the role and business models of life sciences in future, as part of a broader transformation of the health value chain. Siniša Belina of AMPLEXOR Life Sciences explores some of the potential opportunities, and considers how companies might start to prepare for what lies ahead. ...

Read More

Clinical Operations and Supply Chain Management: Sharing Perspectives to Maximise Patient Benefits

Aug 6, 2018

Predicting patient enrolment in clinical trials is challenging. While early enrolment forecasts are often evolving, they are required by clinical supply groups to establish drug demand. The link between enrolment forecast and drug waste can be a source of frustration between clinical operations and clinical supply groups. How can supply planners create accurate drug forecasts from uncertain enrolment forecasts? In this article, Louise Oliver and Luke Moyer from the Almac Group contend that synergy is the key to optimising supply and maximising patient benefits. ...

Read More

GS1 Standards: Making Pharmacy Fit for the Future

Aug 6, 2018

As our healthcare system faces increasing pressure to improve safety and efficiency, and to be a world leader in delivering care, for pharmacy this translates into the challenge of keeping medicines safe, using them more cost-effectively and keeping up to date with the latest legislation and technology. Counterfeit drugs are a global problem, and medicines spend is one of the biggest costs to the NHS. Legislation such as the Falsified Medicines Directive will make our pharmacies safer and central initiatives such as the Global Digital Exemplar programme are pushing Trusts to stay ahead of the game in their use of ...

Read More

The Excipient Challenge

Aug 6, 2018

Excipients are defined as any component(s) of a dosage form other than the drug substance. They are added for the purposes of enhancing production, aiding patient acceptability, improving stability and/or controlling release. Moreover, they play an important role in enhancing the processability and bioavailability of drugs by modifying their solubility and/or permeability, which is important information when selecting excipients for any new formulation. This article by Dr Carolina Diaz Quijano from OMYA explores the potential of minerals such as functionalised calcium carbonate, and what kind of formulations it will make possible in the near future. ...

Read More

What Pharma Producers Need to Know About Changing Regulations on Cleanroom Films and Anti-static Additives

Aug 6, 2018

With new USP <661.1> regulations on plastic packaging materials for pharmaceuticals set to take effect in May 2020, and following this, USP <665> (formerly known as USP <661.3>) for plastics used in the drug manufacturing process bringing new requirements, it is decision time for processors and pharmaceutical users of anti-static polyethylene and polypropylene films. In his article, Steve Duckworth from Clariant provides an overview of these changes and how to be sure to protect the value of in-process APIs and finished drug products. ...

Read More